Teletherapy and Medication Management of Attention-Deficit/Hyperactivity Disorder with Co-occurring Internalizing Symptoms and Suicidality During the Pandemic.

IF 1.8 3区 医学 Q3 BEHAVIORAL SCIENCES Journal of Developmental and Behavioral Pediatrics Pub Date : 2024-11-08 DOI:10.1097/DBP.0000000000001324
Heather Potts, Deepika Shaligram, Rose Ashraf, Elizabeth Diekroger, Jason Fogler
{"title":"Teletherapy and Medication Management of Attention-Deficit/Hyperactivity Disorder with Co-occurring Internalizing Symptoms and Suicidality During the Pandemic.","authors":"Heather Potts, Deepika Shaligram, Rose Ashraf, Elizabeth Diekroger, Jason Fogler","doi":"10.1097/DBP.0000000000001324","DOIUrl":null,"url":null,"abstract":"<p><strong>Case: </strong>Sam (he/him) is an 11-year-old cisgender white male with previous diagnoses of attention-deficit/hyperactivity disorder, anxiety, and major depressive disorder who was referred to an outpatient psychiatry clinic after hospitalization for suicidal ideation and agitation. Family history is significant for bipolar disorder, depression, anxiety, substance use/abuse, and suicidality. Sam started a trial of atomoxetine 10 mg po QAM in December 2019 due to increasing inattention in the backdrop of worsening anxiety. Sam received school-based counseling through his IEP, which Sam declined due to embarrassment from being pulled out of the classroom, and services were quickly discontinued. In January 2020, obsessive-compulsive symptoms emerged, specifically obsessions about cleanliness with related compulsions. He started biweekly cognitive behavioral therapy with an outpatient provider to target obsessive-compulsive disorder symptoms. Concomitantly, a developmental-behavioral pediatrician who diagnosed obsessive-compulsive disorder started Sam on fluoxetine 10 mg po QAM. Atomoxetine was also increased to 25 mg po QAM for 4 weeks and built up to 40 mg po QAM in February 2020.Depressive symptoms emerged in Spring 2020, around the time of the COVID-19 pandemic, despite ongoing treatment with fluoxetine. There was a significant increase in aggression, agitation, and compulsive cleaning, which did not respond to the addition of lorazepam 0.5 mg po daily. Owing to concerns that medication was exacerbating his presentation, his prescriber began to wean him off both atomoxetine and fluoxetine.Sam presented to the Emergency Department in the summer of 2020 due to worsening symptoms, including suicidal ideation and aggression, in the context of medication adjustment, social isolation, and academic difficulty with virtual schooling. He completed a 3-week inpatient hospitalization followed by a 2-week virtual partial hospitalization program, during which Sam struggled with attention and engagement. As part of his discharge plan, he was referred to the outpatient psychiatry department to continue outpatient therapy and medication management.During the virtual transfer appointment to outpatient therapy, his parents reported persistent concerns for ongoing attention-deficit/hyperactivity disorder, depression, anxiety, and obsessive-compulsive symptoms, along with a fear of a resurgence of suicidal thinking. Sam reported exhaustion from virtual partial hospitalization program sessions he attended earlier in the day and was eager to leave the appointment. He minimized concerns, denied suicidal ideation or intent, and reported a strong disinterest in doing \"another virtual therapy.\" In-person sessions would be ideal for Sam, given his history of attention difficulties, clinical complexity, and acuity and his self-identified dislike for virtual settings. However, services needed to be done virtually due to the quarantine shutdown. How would you proceed with treating Sam?</p>","PeriodicalId":50215,"journal":{"name":"Journal of Developmental and Behavioral Pediatrics","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Developmental and Behavioral Pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/DBP.0000000000001324","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BEHAVIORAL SCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Case: Sam (he/him) is an 11-year-old cisgender white male with previous diagnoses of attention-deficit/hyperactivity disorder, anxiety, and major depressive disorder who was referred to an outpatient psychiatry clinic after hospitalization for suicidal ideation and agitation. Family history is significant for bipolar disorder, depression, anxiety, substance use/abuse, and suicidality. Sam started a trial of atomoxetine 10 mg po QAM in December 2019 due to increasing inattention in the backdrop of worsening anxiety. Sam received school-based counseling through his IEP, which Sam declined due to embarrassment from being pulled out of the classroom, and services were quickly discontinued. In January 2020, obsessive-compulsive symptoms emerged, specifically obsessions about cleanliness with related compulsions. He started biweekly cognitive behavioral therapy with an outpatient provider to target obsessive-compulsive disorder symptoms. Concomitantly, a developmental-behavioral pediatrician who diagnosed obsessive-compulsive disorder started Sam on fluoxetine 10 mg po QAM. Atomoxetine was also increased to 25 mg po QAM for 4 weeks and built up to 40 mg po QAM in February 2020.Depressive symptoms emerged in Spring 2020, around the time of the COVID-19 pandemic, despite ongoing treatment with fluoxetine. There was a significant increase in aggression, agitation, and compulsive cleaning, which did not respond to the addition of lorazepam 0.5 mg po daily. Owing to concerns that medication was exacerbating his presentation, his prescriber began to wean him off both atomoxetine and fluoxetine.Sam presented to the Emergency Department in the summer of 2020 due to worsening symptoms, including suicidal ideation and aggression, in the context of medication adjustment, social isolation, and academic difficulty with virtual schooling. He completed a 3-week inpatient hospitalization followed by a 2-week virtual partial hospitalization program, during which Sam struggled with attention and engagement. As part of his discharge plan, he was referred to the outpatient psychiatry department to continue outpatient therapy and medication management.During the virtual transfer appointment to outpatient therapy, his parents reported persistent concerns for ongoing attention-deficit/hyperactivity disorder, depression, anxiety, and obsessive-compulsive symptoms, along with a fear of a resurgence of suicidal thinking. Sam reported exhaustion from virtual partial hospitalization program sessions he attended earlier in the day and was eager to leave the appointment. He minimized concerns, denied suicidal ideation or intent, and reported a strong disinterest in doing "another virtual therapy." In-person sessions would be ideal for Sam, given his history of attention difficulties, clinical complexity, and acuity and his self-identified dislike for virtual settings. However, services needed to be done virtually due to the quarantine shutdown. How would you proceed with treating Sam?

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在大流行病期间,对同时伴有内化症状和自杀倾向的注意力缺陷/多动障碍进行远程治疗和药物管理。
病例:萨姆(他/他)是一名 11 岁的顺性别白人男性,曾被诊断患有注意力缺陷/多动障碍、焦虑症和重度抑郁障碍。该患者有严重的双相情感障碍、抑郁、焦虑、药物使用/滥用和自杀等家族病史。由于在焦虑症恶化的背景下注意力越来越不集中,山姆于2019年12月开始试用阿托莫西汀10毫克,每次QAM。通过个人教育计划,萨姆接受了学校提供的心理咨询,但由于被拉出教室而感到尴尬,萨姆拒绝接受这种服务,而且这种服务很快就停止了。2020 年 1 月,萨姆出现了强迫症状,特别是对清洁的强迫和相关的强迫症。他开始接受每两周一次的认知行为治疗,由一名门诊医生针对强迫症症状进行治疗。与此同时,一名诊断出强迫症的儿科发育行为医生开始给山姆服用氟西汀,每次 10 毫克。尽管一直在接受氟西汀治疗,但在 2020 年春季,即 COVID-19 大流行前后,抑郁症状还是出现了。攻击性、烦躁不安和强迫性清洁症状明显增加,但在每天服用 0.5 毫克劳拉西泮后症状并无好转。由于担心药物会加重他的症状,处方医生开始让他停用阿托西汀和氟西汀。2020 年夏天,萨姆因症状加重(包括自杀意念和攻击性)、药物调整、社会隔离和虚拟学校学习困难而到急诊科就诊。他接受了为期 3 周的住院治疗,随后又接受了为期 2 周的虚拟部分住院治疗项目,在此期间,萨姆在注意力和参与度方面都遇到了困难。作为出院计划的一部分,他被转介到精神科门诊部继续接受门诊治疗和药物管理。在门诊治疗的虚拟转诊预约期间,他的父母报告说,他们一直担心萨姆会持续出现注意力缺陷/多动障碍、抑郁、焦虑和强迫症状,并担心他再次出现自杀念头。萨姆报告说,他在当天早些时候参加的虚拟部分住院治疗项目课程中感到疲惫不堪,急于离开预约地点。他将担忧降到最低,否认有自杀想法或意图,并表示对 "再做一次虚拟治疗 "非常不感兴趣。考虑到萨姆有注意力障碍、临床复杂性和敏锐性的病史,以及他自称不喜欢虚拟环境,面对面的治疗对他来说是最理想的。但是,由于隔离关闭,服务需要以虚拟方式进行。您将如何对山姆进行治疗?
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.10
自引率
8.30%
发文量
155
审稿时长
6-12 weeks
期刊介绍: Journal of Developmental & Behavioral Pediatrics (JDBP) is a leading resource for clinicians, teachers, and researchers involved in pediatric healthcare and child development. This important journal covers some of the most challenging issues affecting child development and behavior.
期刊最新文献
Nocebo Effect on Pain Perception and Attention with Children With and Without Attention Deficit And/Or Hyperactivity Disorder. Associations Between Sleep Health and Child Behavior at Age 6 Years in the INSIGHT Study. Teletherapy and Medication Management of Attention-Deficit/Hyperactivity Disorder with Co-occurring Internalizing Symptoms and Suicidality During the Pandemic. Boosting Autism Screening and Referrals with EHR-Integrated Tools at Well-Child Visits. Challenging Case: Family Navigation for Autism Spectrum Disorder.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1